Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05288166




Registration number
NCT05288166
Ethics application status
Date submitted
10/03/2022
Date registered
21/03/2022
Date last updated
26/06/2024

Titles & IDs
Public title
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Scientific title
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Secondary ID [1] 0 0
I3Y-MC-JPEG
Secondary ID [2] 0 0
18448
Universal Trial Number (UTN)
Trial acronym
CYCLONE 3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prostatic Neoplasms 0 0
Neoplasm Metastasis 0 0
Urogenital Neoplasms 0 0
Physiological Effects of Drugs 0 0
Antineoplastic Agents 0 0
Antineoplastic Agents, Hormonal 0 0
Androgens 0 0
Hormones 0 0
Hormones, Hormone Substitutes, and Hormone Antagonists 0 0
Abiraterone Acetate 0 0
Steroid Synthesis Inhibitors 0 0
Cytochrome P-450 0 0
Enzyme Inhibitors 0 0
Prednisone 0 0
Prednisolone 0 0
Cyclin-Dependent Kinase 4 0 0
Cyclin-Dependent Kinase 6 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate
Cancer 0 0 0 0
Other cancer types
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Inflammatory and Immune System 0 0 0 0
Allergies

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Abemaciclib
Treatment: Drugs - Abiraterone
Treatment: Drugs - Prednisone or Prednisolone
Treatment: Drugs - Placebo for Abemaciclib

Experimental: Abemaciclib + Abiraterone + Prednisone/Prednisolone - Abemaciclib plus (+) abiraterone + prednisone/prednisolone administered orally.

Active comparator: Placebo + Abiraterone + Prednisone/Prednisolone - Placebo + abiraterone + prednisone/prednisolone administered orally.


Treatment: Drugs: Abemaciclib
Administered orally.

Treatment: Drugs: Abiraterone
Administered orally.

Treatment: Drugs: Prednisone or Prednisolone
Administered orally.

Treatment: Drugs: Placebo for Abemaciclib
Administered orally.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Radiographic Progression-Free Survival (rPFS) Assessed by Investigator
Timepoint [1] 0 0
Randomization to radiographic progression or death from any cause (approximately 48 months)
Secondary outcome [1] 0 0
rPFS Assessed by Blinded Independent Central Review (BICR)
Timepoint [1] 0 0
Randomization to radiographic progression or death from any cause (approximately 48 months)
Secondary outcome [2] 0 0
Castration-resistant Prostate Cancer (CRPC)-free Survival
Timepoint [2] 0 0
Randomization to the earliest date of PSA or radiographic progression with a testosterone level of =50 nanogram/deciliter (ng/dL); or death from any cause (approximately 48 months)
Secondary outcome [3] 0 0
Overall Survival (OS)
Timepoint [3] 0 0
Baseline to date of death due to any cause (approximately 60 months)
Secondary outcome [4] 0 0
Time to Pain Progression
Timepoint [4] 0 0
Randomization to pain progression (approximately 48 months)
Secondary outcome [5] 0 0
Time to Deterioration in Health-Related Quality of Life (HRQoL)
Timepoint [5] 0 0
Randomization to the date of HRQoL deterioration (approximately 48 Months)
Secondary outcome [6] 0 0
Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib
Timepoint [6] 0 0
Postdose Cycle 1 Day 1 through Predose Cycle 3 Day 1 (28 Day Cycles)

Eligibility
Key inclusion criteria
* Adenocarcinoma of the prostate (as the predominant histology)
* High-risk metastatic hormone-sensitive prostate cancer. High risk is defined as:

* Greater than or equal to (=)4 bone metastases by bone scan and/or
* =1 visceral metastases by computed tomography or magnetic resonance imaging
* Must have initiated androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or bilateral orchiectomy prior to randomization. Up to 3 months of ADT prior to randomization is permitted with or without first-generation anti-androgen.
* Adequate organ function
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior treatment with abemaciclib or any other cyclin dependent kinase 4 and 6 (CDK4 & 6) inhibitor
* Development of metastatic prostate cancer in the context of castrate levels of testosterone
* Received any prior systemic therapy for metastatic prostate cancer (including investigational agents), except for ADT and first-generation anti-androgen
* Clinically significant cardiovascular disease as evidenced by myocardial infarction, arterial thrombotic events, or severe/unstable angina in the past 6 months, or New York Heart Association Class II to IV heart failure
* History of syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin, or sudden cardiac arrest. Chronic and hemodynamically stable atrial arrhythmia well-controlled on medical therapy is permitted
* Uncontrolled hypertension
* Clinically active or chronic liver disease, moderate/severe hepatic impairment
* Known untreated central nervous system (CNS) metastasis. Participants with a history of treated brain metastases are eligible if stable for at least 8 weeks prior to randomization and off corticosteroid for at least 2 weeks prior to randomization

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/04/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/10/2027
Actual
Sample size
Target
900
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,South AustTAS,VIC,WA
Recruitment hospital [1] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment hospital [2] 0 0
Coffs Harbour Health Campus - Coffs Harbour
Recruitment hospital [3] 0 0
St Vincent's Hospital - Darlinghurst
Recruitment hospital [4] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [5] 0 0
Macquarie University - Macquarie University
Recruitment hospital [6] 0 0
Icon Cancer Centre South Brisbane - South Brisbane
Recruitment hospital [7] 0 0
Tasman Oncology Research - Southport
Recruitment hospital [8] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [9] 0 0
Lyell McEwin Hospital - Elizabeth Vale
Recruitment hospital [10] 0 0
Ashford Cancer Centre Research - Kurralta Park
Recruitment hospital [11] 0 0
Icon Cancer Centre Hobart - Hobart
Recruitment hospital [12] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [13] 0 0
Monash Health - Clayton
Recruitment hospital [14] 0 0
Barwon Health - Geelong
Recruitment hospital [15] 0 0
Austin Health - Heidelberg
Recruitment hospital [16] 0 0
St Vincent's Hospital - Melbourne
Recruitment hospital [17] 0 0
Epworth Freemasons - Richmond
Recruitment hospital [18] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2450 - Coffs Harbour
Recruitment postcode(s) [3] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [4] 0 0
2170 - Liverpool
Recruitment postcode(s) [5] 0 0
2109 - Macquarie University
Recruitment postcode(s) [6] 0 0
4101 - South Brisbane
Recruitment postcode(s) [7] 0 0
4215 - Southport
Recruitment postcode(s) [8] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [9] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [10] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [11] 0 0
7000 - Hobart
Recruitment postcode(s) [12] 0 0
3128 - Box Hill
Recruitment postcode(s) [13] 0 0
3168 - Clayton
Recruitment postcode(s) [14] 0 0
3220 - Geelong
Recruitment postcode(s) [15] 0 0
3084 - Heidelberg
Recruitment postcode(s) [16] 0 0
3065 - Melbourne
Recruitment postcode(s) [17] 0 0
3121 - Richmond
Recruitment postcode(s) [18] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Tennessee
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
United States of America
State/province [20] 0 0
Utah
Country [21] 0 0
United States of America
State/province [21] 0 0
Vermont
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Air
Country [25] 0 0
Argentina
State/province [25] 0 0
Ciudad Autónoma De Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Ciudad Autónoma De Buenos Aire
Country [27] 0 0
Argentina
State/province [27] 0 0
Córdoba
Country [28] 0 0
Argentina
State/province [28] 0 0
Río Negro
Country [29] 0 0
Argentina
State/province [29] 0 0
Tucumán
Country [30] 0 0
Argentina
State/province [30] 0 0
San Juan
Country [31] 0 0
Belgium
State/province [31] 0 0
Oost-Vlaanderen
Country [32] 0 0
Belgium
State/province [32] 0 0
West-Vlaanderen
Country [33] 0 0
Belgium
State/province [33] 0 0
Namur
Country [34] 0 0
Brazil
State/province [34] 0 0
Bahia
Country [35] 0 0
Brazil
State/province [35] 0 0
Ceará
Country [36] 0 0
Brazil
State/province [36] 0 0
Minas Gerais
Country [37] 0 0
Brazil
State/province [37] 0 0
Paraná
Country [38] 0 0
Brazil
State/province [38] 0 0
Rio Grande Do Sul
Country [39] 0 0
Brazil
State/province [39] 0 0
Santa Catarina
Country [40] 0 0
Brazil
State/province [40] 0 0
São Paulo
Country [41] 0 0
Brazil
State/province [41] 0 0
Rio de Janeiro
Country [42] 0 0
Canada
State/province [42] 0 0
Ontario
Country [43] 0 0
China
State/province [43] 0 0
Anhui
Country [44] 0 0
China
State/province [44] 0 0
Beijing
Country [45] 0 0
China
State/province [45] 0 0
Guangdong
Country [46] 0 0
China
State/province [46] 0 0
Heilongjiang
Country [47] 0 0
China
State/province [47] 0 0
Hubei
Country [48] 0 0
China
State/province [48] 0 0
Hunan
Country [49] 0 0
China
State/province [49] 0 0
Jiangsu
Country [50] 0 0
China
State/province [50] 0 0
Jiangxi
Country [51] 0 0
China
State/province [51] 0 0
Jilin
Country [52] 0 0
China
State/province [52] 0 0
Shaanxi
Country [53] 0 0
China
State/province [53] 0 0
Shandong
Country [54] 0 0
China
State/province [54] 0 0
Shanghai
Country [55] 0 0
China
State/province [55] 0 0
Sichuan
Country [56] 0 0
China
State/province [56] 0 0
Tianjin
Country [57] 0 0
China
State/province [57] 0 0
Zhejiang
Country [58] 0 0
Czechia
State/province [58] 0 0
Beroun
Country [59] 0 0
Czechia
State/province [59] 0 0
Brno-mesto
Country [60] 0 0
Czechia
State/province [60] 0 0
Jihomoravský Kraj
Country [61] 0 0
Czechia
State/province [61] 0 0
Praha 10
Country [62] 0 0
Czechia
State/province [62] 0 0
Praha 4
Country [63] 0 0
Czechia
State/province [63] 0 0
Príbram
Country [64] 0 0
Czechia
State/province [64] 0 0
Hradec Kralove
Country [65] 0 0
Czechia
State/province [65] 0 0
Prague
Country [66] 0 0
France
State/province [66] 0 0
Bretagne
Country [67] 0 0
France
State/province [67] 0 0
Centre
Country [68] 0 0
France
State/province [68] 0 0
Côte-d'Or
Country [69] 0 0
France
State/province [69] 0 0
Doubs
Country [70] 0 0
France
State/province [70] 0 0
Languedoc-Roussillon
Country [71] 0 0
France
State/province [71] 0 0
Loire-Atlantique
Country [72] 0 0
France
State/province [72] 0 0
Provence-Alpes-Côte-d'Azur
Country [73] 0 0
France
State/province [73] 0 0
Rhône-Alpes
Country [74] 0 0
France
State/province [74] 0 0
Sarthe
Country [75] 0 0
France
State/province [75] 0 0
Paris
Country [76] 0 0
Germany
State/province [76] 0 0
Baden-Württemberg
Country [77] 0 0
Germany
State/province [77] 0 0
Baden-Würt
Country [78] 0 0
Germany
State/province [78] 0 0
Bayern
Country [79] 0 0
Germany
State/province [79] 0 0
Hessen
Country [80] 0 0
Germany
State/province [80] 0 0
Nordrhein-Westfalen
Country [81] 0 0
Germany
State/province [81] 0 0
Nordrhein-
Country [82] 0 0
Germany
State/province [82] 0 0
Rheinland-Pfalz
Country [83] 0 0
Germany
State/province [83] 0 0
Hamburg
Country [84] 0 0
Germany
State/province [84] 0 0
Mettmann
Country [85] 0 0
Germany
State/province [85] 0 0
Nürnberg
Country [86] 0 0
Greece
State/province [86] 0 0
Acha?a
Country [87] 0 0
Greece
State/province [87] 0 0
Attikí
Country [88] 0 0
Greece
State/province [88] 0 0
Irakleío
Country [89] 0 0
Hungary
State/province [89] 0 0
Bács-Kiskun
Country [90] 0 0
Hungary
State/province [90] 0 0
Gyor-Moson-Sopron
Country [91] 0 0
Hungary
State/province [91] 0 0
Pest
Country [92] 0 0
Hungary
State/province [92] 0 0
Budapest
Country [93] 0 0
Israel
State/province [93] 0 0
HaMerkaz
Country [94] 0 0
Israel
State/province [94] 0 0
HaTsafon
Country [95] 0 0
Israel
State/province [95] 0 0
Tell Abib
Country [96] 0 0
Israel
State/province [96] 0 0
Yerushalayim
Country [97] 0 0
Italy
State/province [97] 0 0
Emilia-Rom
Country [98] 0 0
Italy
State/province [98] 0 0
Lazio
Country [99] 0 0
Italy
State/province [99] 0 0
Lombardia
Country [100] 0 0
Italy
State/province [100] 0 0
Veneto
Country [101] 0 0
Italy
State/province [101] 0 0
Milano
Country [102] 0 0
Italy
State/province [102] 0 0
Terni
Country [103] 0 0
Italy
State/province [103] 0 0
Trento
Country [104] 0 0
Japan
State/province [104] 0 0
Aichi
Country [105] 0 0
Japan
State/province [105] 0 0
Chiba
Country [106] 0 0
Japan
State/province [106] 0 0
Hokkaido
Country [107] 0 0
Japan
State/province [107] 0 0
Hyogo
Country [108] 0 0
Japan
State/province [108] 0 0
Ishikawa
Country [109] 0 0
Japan
State/province [109] 0 0
Kagawa
Country [110] 0 0
Japan
State/province [110] 0 0
Kanagawa
Country [111] 0 0
Japan
State/province [111] 0 0
Nagano
Country [112] 0 0
Japan
State/province [112] 0 0
Shizuoka
Country [113] 0 0
Japan
State/province [113] 0 0
Tokyo
Country [114] 0 0
Japan
State/province [114] 0 0
Kumamoto
Country [115] 0 0
Japan
State/province [115] 0 0
Osaka
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Seoul-teukbyeolsi [Seoul]
Country [117] 0 0
Mexico
State/province [117] 0 0
Distrito Federal
Country [118] 0 0
Mexico
State/province [118] 0 0
Jalisco
Country [119] 0 0
Mexico
State/province [119] 0 0
Nuevo León
Country [120] 0 0
Mexico
State/province [120] 0 0
Sinaloa
Country [121] 0 0
Mexico
State/province [121] 0 0
Chihuahua
Country [122] 0 0
Mexico
State/province [122] 0 0
Oaxaca
Country [123] 0 0
Netherlands
State/province [123] 0 0
Noord-Brabant
Country [124] 0 0
Netherlands
State/province [124] 0 0
Groningen
Country [125] 0 0
Poland
State/province [125] 0 0
Lubelskie
Country [126] 0 0
Poland
State/province [126] 0 0
Opolskie
Country [127] 0 0
Poland
State/province [127] 0 0
Pomorskie
Country [128] 0 0
Poland
State/province [128] 0 0
Lódzkie
Country [129] 0 0
Romania
State/province [129] 0 0
Bra?ov
Country [130] 0 0
Romania
State/province [130] 0 0
Cluj
Country [131] 0 0
Romania
State/province [131] 0 0
Constan?a
Country [132] 0 0
Romania
State/province [132] 0 0
Dolj
Country [133] 0 0
Romania
State/province [133] 0 0
Ilfov
Country [134] 0 0
Romania
State/province [134] 0 0
Maramure?
Country [135] 0 0
Romania
State/province [135] 0 0
Bucure?ti
Country [136] 0 0
Spain
State/province [136] 0 0
Barcelona [Barcelona]
Country [137] 0 0
Spain
State/province [137] 0 0
Madrid, Comunidad De
Country [138] 0 0
Spain
State/province [138] 0 0
Valenciana, Comunitat
Country [139] 0 0
Spain
State/province [139] 0 0
Badajoz
Country [140] 0 0
Spain
State/province [140] 0 0
Sevilla
Country [141] 0 0
Taiwan
State/province [141] 0 0
Taipei
Country [142] 0 0
Taiwan
State/province [142] 0 0
Taichung
Country [143] 0 0
Taiwan
State/province [143] 0 0
Tainan
Country [144] 0 0
Taiwan
State/province [144] 0 0
Taoyuan
Country [145] 0 0
Turkey
State/province [145] 0 0
Istanbul
Country [146] 0 0
Turkey
State/province [146] 0 0
Izmir
Country [147] 0 0
Turkey
State/province [147] 0 0
Adana
Country [148] 0 0
Turkey
State/province [148] 0 0
Ankara
Country [149] 0 0
Turkey
State/province [149] 0 0
Diyarbakir
Country [150] 0 0
Turkey
State/province [150] 0 0
Edirne
Country [151] 0 0
Turkey
State/province [151] 0 0
Malatya
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Blackburn With Darwen
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Essex
Country [154] 0 0
United Kingdom
State/province [154] 0 0
London, City Of

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
Trial website
https://clinicaltrials.gov/study/NCT05288166
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries